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Abstract
Vaccination for the control of bovine tuberculosis (bTB) in cattle is not currently used within
any international control program, and is illegal within the EU. Candidate vaccines, based
upon Mycobacterium bovis bacillus Calmette-Guérin (BCG) all interfere with the action of
the tuberculin skin test, which is used to determine if animals, herds and countries are offi-
cially bTB-free. New diagnostic tests that Differentiate Infected from Vaccinated Animals
(DIVA) offer the potential to introduce vaccination within existing eradication programs. We
use within-herd transmission models estimated from historical data from Great Britain (GB)
to explore the feasibility of such supplemental use of vaccination. The economic impact of
bovine Tuberculosis for farmers is dominated by the costs associated with testing, and as-
sociated restrictions on animal movements. Farmers’ willingness to adopt vaccination will
require vaccination to not only reduce the burden of infection, but also the risk of restrictions
being imposed. We find that, under the intensive sequence of testing in GB, it is the specific-
ity of the DIVA test, rather than the sensitivity, that is the greatest barrier to see a herd level
benefit of vaccination. The potential negative effects of vaccination could be mitigated
through relaxation of testing. However, this could potentially increase the hidden burden of
infection within Officially TB Free herds. Using our models, we explore the range of the
DIVA test characteristics necessary to see a protective herd level benefit of vaccination. We
estimate that a DIVA specificity of at least 99.85% and sensitivity of>40% is required to see
a protective benefit of vaccination with no increase in the risk of missed infection. Data from
experimentally infected animals suggest that this target specificity could be achieved in vac-
cinates using a cocktail of three DIVA antigens while maintaining a sensitivity of 73.3%
(95%CI: 61.9, 82.9%) relative to post-mortem detection.
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Author Summary
Bovine tuberculosis (bTB) is a major economic disease of livestock worldwide. Despite an
intensive, and costly, control program in the United Kingdom, bTB continues to persist.
Vaccination can provide some protection to cattle, but is currently illegal within the Euro-
pean Union due to the interaction of BCG with the action of the tuberculin skin test. The
EU has signaled that changes in legislation will require field validation of BCG as a supple-
ment to existing controls. A particular concern is that the imperfect sensitivity of prospec-
tive DIVA tests for vaccinates may increase the chances of infection being missed within
herds. However, we demonstrate that high DIVA specificity will also be essential in order
for farmers to see a protective herd level benefit of vaccination in terms of the frequency of
tests they are subjected to and number of animals condemned. Field validation of the
DIVA test will be an essential prerequisite to use of BCG in the field. Our estimated target
specificity provides an important criterion for validation of prospective DIVA tests before
deployment in the field.
Introduction
Human vaccineMycobacterium bovis bacillus Calmette-Guérin (BCG) vaccination has been
shown to induce significant levels of protection in cattle in a large number of experimental
studies and field trials since 1912 (reviewed in [1]). More recent laboratory studies have dem-
onstrated significant reductions in the development and presentation of visible lesions after
challenge withM. bovis [2]. Recent field trials and experiments under natural transmission
conditions have also reported its effectiveness, although with variable levels of protection [3],
[4] ranging from no effect to up to individual protective efficacies of 68% [5]. However, vacci-
nation is not currently used as part of a national bovine TB control program. By far the most
important historical barrier to the use of cattle vaccination is the interference of BCG with the
specificity of the tuberculin skin test [6], which is the cornerstone of surveillance and eradica-
tion strategies [7]. A new generation of diagnostic DIVA tests that can Differentiate Vaccinated
from Infected Animals [8], [9] opens up the opportunity for the use of BCG within current
control programs. For vaccination to be feasible economically and useful within the context of
European legislation, the benefits of vaccination must be great enough to outweigh any increase
in testing associated with the efficiency of DIVA testing. In this study we use rigorously esti-
mated within-herd transmission models [7] to explore scenarios for the supplemental use of
BCG vaccination in Great Britain. We estimate the DIVA test characteristics necessary to see a
protective herd level benefit of vaccination when used within the current statutory system
of testing.
Control ofM. bovis infection of cattle in Great Britain, and internationally, generally de-
pends on active disease surveillance through repeated testing of herds using tuberculin. The se-
quence of testing used has been designed around the known imperfect sensitivity and
specificity of the tuberculin test. A fundamental challenge to the evaluation of diagnostic tests
for bTB in GB is that test-positive animals are slaughtered irrespective of development of phys-
ical symptoms of disease. In the absence of a gold standard, the sensitivity and specificity of di-
agnostic tests can only be directly measured relative to culture confirmation of visible lesions.
In this paper, unless otherwise stated, we define (and estimate) the sensitivity and specificity of
diagnostic tests relative to the true infection status of animals. In our modelling framework we
therefore define the specificity of a test as the complement (1-pFP) of the probability of obtain-
ing a false-positive test result (pFP).
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In the UK, the single Intra-dermal Cervical Comparative Tuberculin (SICCT) test is em-
ployed, which controls for cross-reactivity resulting from exposure to other related environ-
mental mycobacteria. Animals are classified as test positive, or reactors, when the difference in
a hypersensitivity reaction to bovine and avian derived tuberculin exceeds a fixed threshold.
The level of this threshold is adjusted to calibrate the sensitivity and specificity of the SICCT
test based upon the testing history of a herd. Under the standard interpretation used for routine
testing in Great Britain, the SICCT test has an exceedingly high estimated specificity of>
99.99% [10] and a sensitivity relative to visible lesions with variable estimates of between
55.1%–95.5% [11], [12].
Once infection is detected within a British herd, movement restrictions are applied and all
bovines within the herd must undergo a statutory sequence of (60 day) short interval testing.
Described as a herd ‘breakdown’, provided that no animals are found to have visible lesions,
the herd is classified as Officially TB-free Suspended (OTF-S) and restrictions are maintained
until the herd passes at least one whole herd test at the standard interpretation [7]. However,
when animals are found with lesions visible at post-mortem, orM. bovis is cultured from them,
the herd is classified as Officially TB-free Withdrawn (OTF-W) and a more severe interpreta-
tion of the test is used, trading off specificity to increase relative test sensitivity with estimates
between 88.5% and 100% [11], [12]. Since laboratory confirmation of lesions is itself insensi-
tive, the true sensitivity of tuberculin testing may be considerably lower than these estimates as
suggested by recent non-gold standard latent class analyses [13]. Inherent in the design of the
sequence of testing using in GB is the desire to optimize the removal of infected animals by an
insensitive, but highly specific, diagnostic test.
In a previous study of the within-herd persistence of bTB we set out to quantify the contri-
bution that these imperfections of tuberculin testing have on the within-herd persistence of in-
fection [7]. We estimated that up to 50% of herds had a median residual burden of infection of
one animal remaining when movement restrictions were lifted. We also found that rates of re-
currence were primarily driven by the rate of re-introduction of infection into the herd, espe-
cially in high incidence regions. However, the time for a herd to clear restrictions was
remarkably consistent between low and high incidence areas (Fig. 1), with herd size and use of
the severe interpretation of the SICCT test being the only clear risk factors associated with the
duration of restrictions [14]. Taken together, these observations suggest that SICCT specificity
is an important determinant of the time for herds to clear restrictions under the current
regulatory regime.
The duration of such movement restrictions is important due to the considerable economic
burden they place on farms. The financial costs to farmers caused by breakdown restrictions
vary massively, depending on a complex range of factors including the farming business
model, the length of restrictions, timing of the breakdown and the individual animals affected
[15]. It is more straightforward to quantify the costs to government, which depend on the
number of visits to farms by veterinarians, tests carried out and compensation for animals con-
demned as reactors, all of which have increased with the growing prevalence of infection over
the last two decades [16]; costs are estimated to be up to £0.5 billion pounds over the last ten
years [17].
Due to the indirect protection afforded by vaccination through herd immunity [18], vacci-
nation is often the most cost-effective method of controlling infectious diseases. Cattle vaccina-
tion has been proposed as a supplementary method to reduce the duration of time that herds
are under restrictions and the number of animals removed during testing. However, such use
poses a particular challenge forM. bovis infection where the known interference of BCG with
tuberculin testing has resulted in cattle vaccination for bTB being prohibited in the EU. Tuber-
culin testing is used to demonstrate progress towards national eradication and also as the basis
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of international trade in cattle. Thus, vaccinated animals that demonstrate sensitivity to tuber-
culin have to be treated as infected animals and slaughtered.
There has recently been movement in this position by the EU and requirements for changes
in legislation to allow cattle vaccination have been outlined, essentially requiring field evalua-
tion of both BCG efficacy and DIVA test characteristics. Recent advice from the European
Food Safety Authority [19], commissioned by the EU, emphasized the importance of demon-
strating that BCG is efficacious and that DIVA tests can be shown to have a comparable sensi-
tivity to tuberculin testing. However, a key factor overlooked in this report was that the
currently viable DIVA tests are based on the gamma-interferon platform, which is known to
have a lower specificity than SICCT testing [8]. This raises the concern that the use of BCG vac-
cination and DIVA tests under the current regulatory system of testing may lead to vaccinated
herds effectively unable to escape restrictions once a single reactor animal has been detected.
Here, we extend our previous work [7], incorporating a more realistic herd demography, es-
sential for assessing the impact of vaccination, into our rigorously estimated within-herd mod-
els of bTB transmission. We explore scenarios for the use of BCG vaccination in combination
with DIVA testing and consider the potential economic benefits relative to the current regime
of tuberculin testing. We wish to explore the potential for economic benefits not only from the
perspective of the government, which currently pays for testing and compensation for test-
positive animal but also the individual farmer. Studies of the financial costs to farmers associat-
ed with bTB restrictions have shown that the financial outcomes of a bTB incident are complex
and highly variable for different farms to the extent that they cannot be summarized through
averages or point estimates. From the perspective of simulation this variability in financial
costs is dependent on specific aspects of farm management and economic variables that have
no meaningful analogues within our epidemiological models [15].
Fig 1. Age-stratified patterns of reactors in Great Britain. A The relative risk of infection by age RR(a) measured relative to the risk for 0–1 year old cattle,
Error bars denote 95% credible intervals. RR(a) is calculated as the ratio of the force of infection for each age group divided by the estimate for the 0–1 year
old group. The force of infection is a combined estimate for all national herds (beef and dairy) calculated from reactor cattle reported between 2004–2009 as
described in [21]. B The probability of “confirmation” of reactor animals by the presence of visible lesions or culture as a function of age at slaughter,
estimated as the proportion of reactor animals within each (200 day) age-class that demonstrated visible lesions or a positive culture result. Estimates are
calculated using all reactor animals from within our study population of herds. The qualitative pattern is robust between different test-types and parish testing
intervals [21].
doi:10.1371/journal.pcbi.1004038.g001
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In the interest of transparency we therefore choose to use indirect proxy measures of eco-
nomic costs based on the probability of restrictions being applied to a herd, the number of tests
and animals condemned as reactors and thus the duration of time that herds are under restric-
tions. The most important of these proxy measures is the risk of restrictions being applied and
subsequently recurring after they have been lifted. In a study of farmer’s attitudes and willing-
ness to pay for cattle vaccination, Bennett and Balcombe found that farmers valued reductions
in the risk of restrictions being applied over the severity of an incident in terms of duration or
animals lost [20]. As such we would contend that reducing the risk of restrictions being applied
to herds is the single most important requirement for cattle vaccination to be accepted and
adopted by farmers.
We demonstrate that DIVA specificity, rather than sensitivity or individual level efficacy, is
the dominant factor determining whether BCG vaccination can provide a protective economic
benefit at the herd level when used as a supplement to existing controls. We explore the extent
to which derogations on the requirements of testing can be used to mitigate the negative effects
of DIVA testing and estimate break-even test characteristics in terms of these key epidemiolog-
ical and economic measures of costs.
Results
Age-structured model
The compartmental models developed in [7] assumed that the movement of animals on and
off a herd occurred at constant herd level turnover rate sampled from the Cattle Tracing Sys-
tem (CTS). As a consequence of this approximation, individuals spend an exponentially dis-
tributed duration of time on herds. In practice the distribution of residence times on herds can
vary considerably between different business models impacting on the herd level rates of re-
moval of residual infection from herds. Implementing these models within an individual based
framework allows us to model more realistic residency times of individuals on herds and more
accurately capture the variation in turnover rates between herds. An additional benefit of the
individual based model framework is that we can also incorporate new evidence for the relative
risk of infection with age and probability of reactor animals demonstrating visible lesions re-
cently estimated by [21] (Fig. 1). After adjusting for testing patterns, we found that young beef
and dairy animals experience a similar infection risk that peaks at 36 months before falling and
plateauing for animals older than five years (Fig. 1A, Table 1). Although the infection risk is
lowest in cattle under 12 months, the highest proportion of skin test positive animals is found
to have visible lesions when they are examined at slaughter (Fig. 1B, Table 2).
We estimate two alternative within-herd transmission (Susceptible-Occult-Reactive-Infec-
tious: SORI, Susceptible-Occult-Reactive: SOR) models that differ in terms of the assumed tim-
ing of the onset of infectiousness. The SORI model is the more traditional view of bTB
progression in cattle [22–24] where susceptible animals (S) must progress through a series of
Table 1. Relative Risk of Infection RR(a).
Age Range(Years) Relative Risk
0–1 1.0
1–2 1.8
2–3 2.3
3–4 1.5
4+ 1.3
doi:10.1371/journal.pcbi.1004038.t001
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latent classes where they are first undetectable (or occult O), detectable (or reactive R) before fi-
nally becoming infectious (I). The SOR model accounts for evidence for the potential ‘early’
transmission of bTB [25] and assumes all infected animals are potentially infectious, but still
differ in their detectability.
Following [7], we use a Sequential Monte Carlo implementation of Approximate Bayesian
Computation (ABC-SMC) [26] for estimation of our models. Within this methodology, infer-
ence of model parameters is based on a set of goodness-of-fit metrics, stratified here by herd
size, parish testing interval (PTI) and whether bTB has been confirmed by culture (OTF-S or
OTF-W status). Until recently, the frequency of routine testing for herds was determined by
the historical herd-level incidence within a parish. As such, for our study population, the fre-
quency at which herds were tested is also a proxy measure for the background risk of infection.
We achieve a comparable fit to our previously published models with respect to the propor-
tion of prolonged and recurrent breakdowns, both indirect measures of the within-herd persis-
tence of infection (Fig. 2). In common with our earlier study [7], both models underestimate
the proportion of OTF-W breakdowns in high incidence (PTI 1) areas and overestimate the
same proportion in low incidence (PTI 4) areas. However, this discrepancy is far smaller than
before with the majority of target values lying within the envelope of the 95%
predictive intervals.
Likewise, both models still underestimate the mean number of reactors, in particular for
breakdowns with no evidence of visible lesions (OTF-S) and for confirmed breakdowns (OTF-
W) in PTI 1. Herd level incidence, as measured by the number of reactor animals removed dur-
ing a breakdown, is remarkably consistent across testing intervals (Fig. 2). Although the predic-
tive distributions are more variable, our new models still struggle to capture this pattern. These
Table 2. Age stratiﬁed probability of reactors with visible lesions/culture positive (PVL(ɑ)).
Age Range (Days) Probability of VL/Culture
0–200 0.58
200–400 0.59
400–600 0.57
600–800 0.50
800–1000 0.41
1000–1200 0.31
1200–1400 0.29
1400–1600 0.27
1600–1800 0.26
1800–2000 0.26
2000–2200 0.28
2200–2400 0.28
2400–2600 0.27
2600–2800 0.28
2800–3000 0.32
3000–3200 0.27
3200–3400 0.31
3400–3600 0.28
3600–3800 0.27
3800–4000 0.28
4000–8000 0.28
doi:10.1371/journal.pcbi.1004038.t002
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patterns arise as incidence in high-risk (PTI 1) herds is strongly constrained by the require-
ment to fit the incidence rate in low-risk PTI 4 herds where infectious animals can potentially
remain within a herd for a longer period of time between routine testing. Classification of
herds purely by testing interval is a crude approximation given that reservoirs of bTB in local
wildlife is likely to generate considerably heterogeneity in the risk of background infection
down to the herd level. Further heterogeneities not accountable within our modeling frame-
work such as geographic variation in the efficiency of surveillance in slaughterhouses [27] or
during routine testing [28] are also likely to contribute to this lack of fit.
Fig 2. Persistence and surveillancemetrics for bTB in GB herds (2003–2011).Within-herd measures of persistence and surveillance used as target
metrics for ABC and to assess model fit. We present four key measures, from left to right: the proportion of prolonged (restrictions of greater duration than 240
days) and recurrent breakdowns, the proportion of herds with evidence of visible lesions and the total number of reactors per breakdown. Breakdowns are
classified as either OTF-S (officially TB free suspended), where no reactors are found to have visible lesions (lime green circles), or OTF-W (officially TB free
withdrawn) where at least one reactor was found to have evidence of visible lesions or be culture positive (magenta squares). The proportion of such OTF-W
breakdowns is shown along with the proportion of these that were initiated by a slaughterhouse case (black circles). The relationship of each measure with
herd size is plotted, with breakdowns further stratified by the historical parish testing interval (A, PTI1; B, PTI 2; C PTI 4) and breakdown status. Mean target
observations are plotted with uncertainty estimated as ±1.96 standard errors around the mean. Predictive distributions from our within-herd (SORI) model for
each of these measures are plotted as shaded density strips where the intensity of color is proportional to the probability density at that point [34].
doi:10.1371/journal.pcbi.1004038.g002
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The model captures the broad characteristics of the age distribution of reactor animals,
slaughterhouse cases and visibly lesioned animals (Fig. 3). However, the assumption that
animals are immediately replaced on removal from herds does introduce a small bias in the
instantaneous age-distribution of herds with a consequently higher proportion of young
(< 2 years) animals and reactors (Fig. 3A,B). There is also a notable discrepancy between the
empirical estimates for the proportion of animals with confirmedM. bovis and model
Fig 3. SORI model fit to age-distributions of reactors. SORI model predictive distributions for the age of reactors (A). Age of “confirmed” reactors with
evidence of visible lesions (B). Slaughterhouse cases (C) and the proportion of animals with visible lesions stratified by age (D). Solid points and lines
indicate empirical target distributions, model predictive distributions are once again overplotted as shaded density strips where the intensity of color is
proportional to the probability density at that point [34].
doi:10.1371/journal.pcbi.1004038.g003
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predictions (Fig. 3D). This is the consequence of approximating the age-dependent probability
of confirmation of reactors using empirical estimates from reactor animals (Table 2). Laborato-
ry confirmation of lesions is assumed to be 100% specific, so logically we must only simulate
the confirmation process for reactors from infected compartments. As a consequence, false
positive reactors reduce the proportion of reactors with visible lesions in simulated output,
with the greatest discrepancy in younger reactors that are less likely to be infected.
Estimates of model parameters are more uncertain than in [7] as a consequence of improved
mixing of parameters in the ABC-SMC procedure and a more realistic representation of inter-
herd variability (S1 Fig.). Several parameters are poorly identified, in particular the reactive pe-
riod, occult period, slaughterhouse detection parameter and density dependence parameter.
This is a consequence of strong trade-offs, in particular between transmission and surveillance
parameters. These trade-offs lead to, in the terminology of Gutenkunst et al. [29], ‘sloppy’ ap-
proximate posterior distributions where a large degree of variability has only a small impact on
model predictions.
Once again we find no clear evidence to choose between the two alternative models. Howev-
er, as we shall see, for the purposes of exploring strategies for vaccination it is DIVA test char-
acteristics that are of primary importance, and interest. For simplicity we only present the
SORI model results, but include equivalent simulations of the SOR model as supplementary in-
formation (S2–S6, S10 Figs.).
Vaccination scenarios
Vaccination is modeled by tracking vaccinated animals, recording the epidemiological status of
each (S7 Fig.). Vaccinates are assumed to have the same rates of disease progression as unvacci-
nated animals, but differ only in their reaction to diagnostic tests and in having a reduced rate
of infection by a factor of ε = (1—individual animal vaccine efficacy). We consider a set of
three vaccination scenarios using different combinations of tuberculin and DIVA testing moti-
vated by discussions with UK government policy teams. All scenarios are based upon an annual
re-vaccination of herds in concert with annual herd tests. TheDIVA Negate scenario adheres
most closely to the current regulatory regime where all animals are tuberculin tested, with tu-
berculin positive vaccinates subject to an additional DIVA test to attempt to negate false posi-
tive reactors. For theDIVA Replacement scenario tuberculin testing is only used for
unvaccinated animals, with vaccinates tested only using a DIVA test. Finally, we consider a
strategy where restrictions are lifted based on the number of animals with confirmedM. bovis
lesions rather than DIVA positivity. Under the VLend scenario testing is carried out as under
DIVA Replacement. However for VLend, short interval testing can be suspended after two
clear tests or two successive tests where DIVA reactors are found to have no confirmed lesions.
We compare each of these scenarios, by challenging newly vaccinated herds with a single in-
fected animal onto the herd. Benefits of vaccination will only be manifested if the vaccinal pro-
tection is sufficient to offset any increase in the number of animal tests, and false positive
reactors, generated by either sensitization to tuberculin or the incomplete specificity of DIVA
testing. We use four key measures of the epidemiological and economic costs associated with
bTB and testing to assess the benefit of vaccination at the herd level: the number of animals
condemned as reactors (R); the number of tests (tuberculin and DIVA) needed to clear restric-
tions (T); the number of infected animals left in herds after restrictions are lifted (burden of in-
fection missed by testing, B) and finally the number of herds that experience a breakdown
before the herd clears the singleton challenge (N).
Cattle Vaccination for Bovine Tuberculosis
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Vaccine efficacy and herd level benefit using γ-interferon DIVA test
Although proof-of-concept experiments have been carried out for a DIVA skin test [9] at the
current time the only viable DIVA test for use in cattle is based on the γ-interferon blood test
platform [8]. This test is similar to comparable tests used to diagnose human TB, such as the
Quantiferon Gold or TSpot assays and with comparable or better performance characteristics
[30]. In common with the SICCT, the interpretation of the γ-interferon DIVA test can be ad-
justed to trade off sensitivity and specificity of the test. The current candidate γ-interferon
DIVA test depends on a combination of response to three antigens: ESAT-6, CFP-10 and
Rv3615c. Data to characterise the response of these antigens have been collected from experi-
mentallyM. bovis infected animals (107 for ESAT-6/CFP-10, 109 for Rv3615c), non-infected
controls (874 for ESAT-6/CFP-10 and 481 for Rv3615c) and a smaller data set of BCG vacci-
nated/experimentally infected animals (75) and BCG vaccinated non-infected controls (214).
We initially selected cut-off values for the three antigens that maximize the DIVA specificity in
the larger data set of unvaccinated animals. Applying these cut-off values to the smaller data
set of BCG vaccinates provides an estimated DIVA sensitivity of 64.4% (95%CI: 48.8, 78.1%)
and 99.4% specificity (95%CI: 96.9–100% CI). Based upon these DIVA test characteristics we
simulated our estimated model over the range of individual protective efficacies ε~[0,1] (Fig. 4
and alternative version with linear scale S9 Fig.).
Across the scenarios considered, vaccination provides a clear protective benefit only in
terms of the residual infection remaining on herds that clear movement restrictions (Fig. 4C).
This marginal benefit comes at a considerable cost in terms of the number of tests necessary to
clear restrictions on herds and the number of animals condemned as reactors under DIVA test-
ing (Fig. 4A,B). Even if we assume that vaccination has 100% efficacy, we fail to see a herd level
benefit of vaccination with over a three-fold increase in the number of animals condemned as
reactors, with a median estimate of 8,663 reactors under theDIVA negate strategy (red) com-
pared to 2,392 under the baseline, no vaccination scenario. Under this same comparison,
DIVA replace is by far the most inefficient strategy with a 32-fold increase in the number of
tests (median estimate of 51,554,010 compared to 1,582,048) and 144-fold increase in the num-
ber of reactors (median estimate of 345,775 compared to 2,392), despite the assumption of
100% efficacy. This difference is driven almost completely by a high rate of false positive reac-
tors due to the lower DIVA specificity. These testing costs are mitigated through the VLend
strategy, although the number of animals removed as reactors is still higher than in the absence
of vaccination (median estimate of 10,277 compared to 2,392).
The relative impact of vaccination within these scenarios is driven almost completely by the
specified test characteristics of the DIVA test, in particular the impact that the relatively low
DIVA specificity compared to SICCT testing has when used within the intensive testing regime
used for GB herds. As such, we expect these results to be largely insensitive to model choice for
within-herd transmission, and indeed we see qualitatively comparable patterns for the alterna-
tive SOR model (see Supplementary Information). This simulation study demonstrates the key
importance of DIVA test performance, rather than individual vaccine efficacy, in determining
the cost-effective use of BCG vaccination in cattle. To explore this question in more detail we
quantify the break-even points for seeing a protective herd level benefit of vaccination as a
function of DIVA test characteristics.
Break-even points for DIVA sensitivity and specificity
To quantify the expected break-even point for DIVA test characteristics we performed a broad
parameter sweep of assumed values of DIVA sensitivity and specificity under our three alterna-
tive testing scenarios. For this comparison we fix efficacy at ε = (1–0.61), corresponding to an
Cattle Vaccination for Bovine Tuberculosis
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individual level efficacy of 61%. We focus on three of our proxy measures relating to costs of
testing: the number of breakdowns (N), number of tests required to clear restrictions (T) and
burden of infection remaining (B). We calculate the probability of seeing a protective benefit
by comparing the distribution of each proxy measure to the baseline distribution for tuberculin
testing alone. These distributions are approximated by 100 posterior draws from our estimated
model and under the vaccination scenario. The probability of benefit is calculated as the
Fig 4. Break-even points for vaccine efficacy under alternative testing scenarios using γ-DIVA test.We estimate the break-even point for a protective
benefit of BCG vaccination at the herd level under three alternative testing scenarios. We model DIVA testing using parameter estimates that optimize DIVA
specificity of 99.4% under the constraint of maintaining a DIVA sensitivity comparable to tuberculin testing of 64.4%.We consider four key measures of the
epidemiological, and economic, costs associated with bTB testing: A the number of animals condemned as reactors; B the number of tests (tuberculin and
DIVA) needed to clear restrictions; C The number of infected animals left in herds after restrictions are lifted (burden of infection missed by testing)D The
number of herds that experience a breakdown before the herd clears the singleton challenge. For all panels, solid black lines indicate the median break-even
point for the baseline scenario with no vaccination. Dashed lines indicate the 95% quantiles of the baseline scenario. The distribution for each measure is
calculated from 100 simulations with parameters drawn from the (approximate) posterior distributions of our estimated model, with each parameter set
simulated once for each herd within our representative study population (of 6,601 herds).
doi:10.1371/journal.pcbi.1004038.g004
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proportion of independent samples where the value from the vaccination scenario is less than
the sample from the baseline scenario.
This probabilistic measure captures the uncertainty and variability in both the parameter es-
timates of our model and due to demographic stochasticity. We consider the break-even point
to be when the probability (proportion) of benefit relative to the baseline of tuberculin testing
only is 0.5.
DIVA negation. Although DIVA negation provides a benefit when DIVA specificity takes
the estimated values used above (Fig. 4) theDIVA replacement and VLend scenarios are clear-
ly more efficient over a wider parameter range thanDIVA negation provided the DIVA speci-
ficity can be raised to a sufficiently high value (Fig. 5). UnderDIVA negation the additional
tests needed to negate tuberculin positive vaccinates overwhelms any protective benefit of vac-
cination in terms of the number of tests (Fig. 5A) and probability of breakdown (Fig. 5B), even
for a DIVA specificity of 100%. It should however be noted that in terms of the number of tests
carried out the maximal probability of benefit under DIVA negation occurs when the sensitivi-
ty of testing is zero and no animals are removed under testing. In this extreme scenario the pro-
tection afforded by vaccination is sufficient to reduce the burden of infection to a comparable
level as tuberculin testing (Fig. 5C) with the increase in duration (and frequency) of break-
downs driven entirely by false positive tuberculin reactions.
DIVA replacement. UnderDIVA replacement, a DIVA specificity of above 99.90% in
combination with an absolute sensitivity of at least 40% can provide a protective benefit of vac-
cination relative to tuberculin testing alone (Fig. 5 D,E,F). This required DIVA specificity is
comparable to the lower bound we place on the specificity of the severe interpretation of the
SICCT test for our model estimates. Once again it is important to note that the relationship be-
tween the probability of benefit and expected costs with DIVA sensitivity is non-linear, with
highly sensitive tests potentially increasing the costs associated with testing at the herd level
(Fig. 5D).
VLend: Changing the endpoint of breakdowns. Changing the endpoint of breakdowns to
depend on evidence of visible lesions in reactor animals can demonstrate a protective benefit
across all three cost measures (Fig. 5 G,H,I) for comparably lower values of DIVA specificity
(although still very high at>99.85%) and sensitivity than underDIVA negation orDIVA re-
placement. Although the negative impacts of DIVA specificity are mitigated under this scenar-
io, as a consequence DIVA sensitivity is more important; a break-even sensitivity of ~40% is
constrained by the risk of leaving infection within the herd (Fig. 5I). Finally, it should be noted
that the magnitude of the benefit under the VLend scenario compared to tuberculin testing
would be considerably less if we used the same end-point definition (i.e. in terms of animals
with VLs) for tuberculin testing in the absence of vaccination.
Discussion
There has recently been a shift in the political landscape with respect to the position of the EU
on introduction of BCG vaccination for cattle. The requirements for changes in legislation to
allow the use of BCG by member states have been detailed in a recent EFSA opinion [19]. Of
central importance is the demonstration of the performance of a suitable DIVA test in large-
scale field trials under European production conditions. The potential risks, and outstanding
challenges, associated with achieving this goal are highlighted in this study.
For vaccination to be tenable it must not only be effective epidemiologically, but must be
cost-effective for individual farmers as well. When the interpretation of the interferon-γ DIVA
test is calibrated to have a comparable sensitivity to SICCT testing, the low specificity relative
to SICCT testing is predicted to considerably increase the costs associated with testing for all
Cattle Vaccination for Bovine Tuberculosis
PLOS Computational Biology | DOI:10.1371/journal.pcbi.1004038 February 19, 2015 12 / 26
Fig 5. Probability of a protective herd level benefit of vaccination for alternative DIVA testing strategies.We explore how the probability of seeing a
protective benefit of vaccination depends on the assumed sensitivity and specificity of DIVA testing. The probability of benefit is calculated for a singleton
challenge of infection and relative to the current statutory regime of tuberculin testing and slaughterhouse surveillance. Benefit is estimated from 100
simulations of our study population (6,601 herds) for three key measures (across columns): the total number of tests required to clear restrictions (A,D,G), the
probability of restrictions being applied before the herd clears infection (B,E,H) and the probability of infection remaining in a herd when restrictions are lifted
(C,F,I). We define the break-even point as 50% of herds demonstrating a protective benefit illustrated by the white band in the color map with red values
worse this threshold and grey points better. We compare the three strategies described in the main text (across rows): (A,B,C) Under the DIVA negation
scenario, the break-even point is limited by the considerable overhead in testing, with an increased probability of restrictions being applied before the herd
clears infection (B) and an increase in testing (A) even for a 100% sensitive and specific DIVA test. (D,E,F) Under DIVA replacement, a protective benefit of
vaccination can be achieved for DIVA specificities> 99.90% (D). The break-even point also depends on DIVA sensitivity, with a sensitivity of at least 40%
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three scenarios we considered. Under this interpretation and for an individual level efficacy of
61%, the median number of tests required to clear restrictions for our study population in-
creases from a baseline estimate of 1,582,048 in the absence of vaccination to 3,674,010 for
DIVA negation, 58,973,457 forDIVA replacement, but remains comparable at 1,592,710 for
the VLend scenario. In model simulations we constrain herds to have a constant size. In prac-
tice the level of false positives generated by the interferon-γDIVA test as modeled here could
lead to the depopulation of whole herds unless the regulations governing the sequencing of
breakdown testing are relaxed (as suggested by the VLend scenario).
The recent EFSA opinion [19] focuses on the requirement that any prospective DIVA test
must be of comparable efficacy to tuberculin testing. This comparison raises considerable ques-
tions as the efficacy of tuberculin testing itself depends on the interpretation of the test and the
relationship between test-positivity and visible lesions. The mechanisms underlying the age-
dependence of reactor rates and lesions with age (Fig. 1) are still poorly understood, as is the
impact that vaccination may have on this picture.
Our herd level models provide an objective measure of the efficiency of testing through the
burden of infection left on herds when restrictions are lifted. Our models suggest that this bur-
den of infection can be reduced in vaccinated herds even when DIVA sensitivity is lower than
SICCT testing—provided that the individual level protection is great enough. Analyzing a re-
cently obtained larger data set (Jones, Vordermeier, personal communication) from BCG vac-
cinated and BCG vaccinated/experimentallyM. bovis infected cattle we explored the potential
to reach this target DIVA specificity in vaccinated animals. We estimate that a relative sensitiv-
ity of the DIVA test of 73.3% (95%CI: 61.9, 82.9%) (using ESAT-6, CFP-10, Rv3615c antigens)
can be achieved at the break-even specificity level of> 99.85. This is comparable to the lower
end of estimates of tuberculin testing in the literature [11]. The potential misclassification of in-
fected individuals by this imperfect gold standard measurement complicates the translation of
empirical estimates of test characteristics to model parameters. In the absence of a true gold-
standard test, the relationship between absolute test characteristics and relative measures can-
not be modeled a priori. Care must therefore be taken in comparing between the absolute test
sensitivity and specificities used as model parameters and estimates relative to the presence of
visible lesions (which is as previously discussed an imperfect diagnostic test itself).
Our analysis demonstrates the challenges inherent in bTB control where we have no gold
standard diagnostic test or clinical manifestation of disease. Incidence and targets for control
of bTB are based on the estimates of prevalence inferred from tuberculin testing. As a conse-
quence, even if an improved diagnostic test was available it could, at least in the short term,
paradoxically apparently increase incidence and the economic costs associated with control.
TheDIVA negate andDIVA replacement scenarios considered in this report demonstrate
that reducing the sensitivity of testing can offset negative effects of imperfect specificity. The
corresponding risk of increasing the probability that infection is left within herd can be esti-
mated from models, however monitoring and quantifying this risk would be an essential re-
quirement for any prospective field trial. In all of the scenarios we have considered vaccination
reduces the burden of infection within herds, and thus the risk of herds moving infected ani-
mals when restrictions are lifted.
being necessary to avoid increased risk of leaving infection in the herd after restrictions are lifted (F). (G,H,I) Under the VLend scenario, linking the
maintenance of restrictions to detection of lesioned reactor animals mitigates the addition costs of testing under other scenarios (G). However, a specificity of
greater than 99.85% is still required to see no increase in the number of breakdowns with vaccination (H), with the break-even point depending again on a
DIVA sensitivity of greater than 40% (I).
doi:10.1371/journal.pcbi.1004038.g005
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Under the current test-and-slaughter regime, the outcome of a bTB breakdown, in practice
and as captured by our models, is highly variable. Systematic heterogeneities between herds
and individuals contribute to this variation, as does uncertainty in the life history of infection.
Fundamentally, this variability is driven by the intrinsically stochastic dynamics of transmis-
sion, detection, and removal of infected animals. For each of our models we aim to capture the
extent of this variability through estimating distributions of parameters rather than point esti-
mates. As a consequence the predicted outcomes of vaccination from our models are highly
variable (Fig. 4). We therefore chose to use probabilistic measures define the break-even point
for vaccination scenarios at the population level (Fig. 5). It is important to acknowledge that
the intrinsic stochasticity of bTB transmission limits the predictive ability of models and
means that strategies that provide an overall benefit at the population level will not guarantee
positive benefits for individual farms.
In conclusion, we found that the efficacy of BCG is largely irrelevant with respect to seeing a
benefit when BCG is introduced with respect to the frequency and duration of restrictions ap-
plied to farms. DIVA specificity, rather than sensitivity, is the biggest barrier to the efficient use
vaccination and indeed to the economic feasibility of field trials of BCG vaccination. Deroga-
tions with respect to the requirement of tuberculin testing vaccinated animals, or changing the
sequence of testing that herds must pass to clear restrictions may help to mitigate these nega-
tive effects. In order to break even under even the most liberal changes to testing considered in
this report (VLend) would require a DIVA specificity of> 99.85%. This value provides a clear
requirement for validation of prospective DIVA tests before deployment in the field.
Methods
Study population
Our within-herd modeling framework estimates rates of transmission and removal of infection
from herds based on the strict timescales imposed by the regulatory structure of the testing re-
gime in Great Britain. The sequence of tests following disclosure of reactor animals places strict
bounds on the duration of time that infection can remain undisclosed within herds. This is not
necessarily true for breakdowns initiated by tracing tests, contiguous testing, inconclusive reac-
tors or follow-up tests following a breakdown. To control for this extra source of variation in
the time-to-detection we restrict our study population to “new” breakdowns that were dis-
closed by routine surveillance tests (classified as VE-WHT, VE-WHT2,VE-RHT,VE-SLH). To
limit the impact of disruptions to testing during the Foot and Mouth Epidemic of 2001 and to
allow enough follow up time to estimate the probability of breakdowns recurring we further
limit our study population to breakdowns with start dates after 1/1/2002 and end dates before
1/9/2009. In a departure from our previous study we place no upper bound on the size of
herds, but do require that herds had a minimum size of 10 animals on the start date of the
breakdown and at least 30 CTS records for the associated CPH. Finally, we excluded any break-
downs where there was discretionary use of γ-interferon testing. This provides us with a study
population of 6,601 herds containing 1,170,541 cattle on the start date of their breakdown.
Target metrics for ABC
We estimate the parameters of our within-herd models using an Approximate Bayesian Com-
putation (ABC) method as described in [7]. ABC is a systematic framework for parameter in-
ference when the likelihood function is intractable or computationally expensive [31].
Parameter estimation is performed through approximating a likelihood function through the
probability of matching model simulations to the observed data using a set of goodness-of-fit
metrics. For our within-herd models, these metrics consist of a set of within-herd persistence
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measures related to the duration and probability of recurrence of breakdowns stratified by the
historical parish testing interval and herd size (Table 1).
For the purpose of model checking we consider an additional set of age-stratified metrics:
the age-distribution of reactor animals, the age-distribution of reactor animals with evidence of
visible lesions, the age-distribution of slaughterhouse cases and the probability of visible lesions
with respect to age (Fig. 1B, Table 2). For the purpose of reproducibility, all target metrics and
anonymised data for each of the study herds are provided as supplementary data tables
(S1 Dataset).
ABC-SMCmethodology
As in [7] we use the ABC-SMC algorithm of [26]. We sampled a set of 1,500 sets of parameters
or particles (Table 3), from a set of uniform prior distributions (Table 4). For each set of pa-
rameters we simulate the model for a single replicate for each of the 6,601 herds in our study
population and calculate the discrepancy between simulations and our set of target metrics
(Table 5). This is a departure from [7], where we simulated multiple (500) replicates of the
model at the median value of the herd-size used to stratify our persistence metrics. The new
method generates more variable simulated output that is more representative of the variability
intrinsic to the size and characteristics of the data set. We then simulate successive rounds
where we accept and reject proposed particles according to a set of tolerances set on our sum-
mary metrics (described above). Newly proposed particles are sampled from the previous
round and perturbed using a multivariate normal kernel with twice the sample variance esti-
mated from the previous round. Convergence of the method is assessed through comparison of
the predictive distributions simulated from the model to our set of target metrics (Figs. 2, 3)
after 30 rounds of ABC-SMC, reducing the tolerance at each step to the 90th percentile of the
particles in the previous round.
Table 3. Model parameters.
Parameter Description
pT Standard SICCT Sensitivity. Probability of positive tuberculin test for (R,I) individuals at
standard deﬁnition.
1-pFP Standard SICCT Speciﬁcity. Probability of negative tuberculin test for S,O,R,I individuals at
standard deﬁnition. (1—probability of a false positive pFP)
p0T Severe SICCT Sensitivity. Probability of positive tuberculin test for R,I individuals at severe
deﬁnition
1 p0FP Severe SICCT Speciﬁcity. Probability of negative tuberculin test for S,O,R,I individuals at
severe deﬁnition.(1—probability of false positivep0FP)
pRI Slaughterhouse detection. Relative sensitivity of ﬁnding lesioned or culture positive animals
(R,I status) under routine inspection compared to reactor inspection
T0 Occult Period. Mean length of time that animals are undetectable (occult) to SICCT
TR Reactive Period. Mean length of time between infection and animals becoming infectious
β Transmission parameter associated with density dependence (rate per day, dimensions
change with q)
q Transmission parameter measuring the strength of density dependence (range 0–1)
χ1 Transmission parameter measuring infectious pressure per susceptible per year in PTI 1
χ2 Transmission parameter measuring infectious pressure per susceptible per year in PTI 2
χ4 Transmission parameter measuring infectious pressure per susceptible per year in PTI 4
Hm = 165 Constant equal to mid-point of range of herd sizes within study population. Used to transform
density dependence of force of infection.
doi:10.1371/journal.pcbi.1004038.t003
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Simulation algorithm
Our epidemiological models are implemented in an individual based framework where we
track information on each animal within the population (Table 6), rather than the number of
individuals within given epidemiological compartments (S,O,R,I. . .). Epidemiological events
are modeled as a continuous-time Markov process [32] defined by the list of events and rates
for the SORI and SOR models detailed in Tables 7 and 8. The demographic events of birth,
death and movement off a herd are simulated as a non-Markov process. The time of each of de-
mographic events is sampled from an extract of the CTS database for each individual animal
added to the model. During each step of the model we simulate the time for the next Markov
event (tMARKOV) and compare to the time of the next non-Markov (demographic) events
(tNON MARKOV). If tNON MARKOV< tMARKOV, we carry out the demographic event first and re-
calculate a new tMARKOV. Otherwise a Markov (epidemiological) event is simulated and the
model time updated.
Demographic events
When the herd is initialized, the birth, death and off-movement times for each individual animal
are sampled using an extract from the CTS database (Table 9). This extract contains four pieces
of information for each animal alive on the start-date of the corresponding breakdown for that
Table 5. Epidemiological target measures for ABC.
Description Type of Measure Number of bins per target
distribution
Weighting
(w
0
j)
Breakdown Length Distribution (Days)
[100,200,300,400,500,1000,2000]
7 1/7
Total reactors removed within breakdown (until
movement restrictions are lifted)
Distribution (Reactors)
[2,4,6,8,10,12,14,16,18,20,47]
11 1/11
Proportion of breakdowns recurring within 24 months Probability 1 1
Proportion of breakdowns conﬁrmed Probability 1 1
Proportion of conﬁrmed breakdowns started by
slaughterhouse case
Probability 1 1
doi:10.1371/journal.pcbi.1004038.t005
Table 4. Prior distributions.
Parameter Prior Constraints Initial sampling distribution
pT 0.01<pT<1 Uniform [0.01, 1]
1-pFP 0<pFP<0.0003 Uniform [0.0,1–0.9997]
p0T pT < p
0
T < 1 Uniform [pT,1]
1 p0FP 0:001 > p0FP > pFP Uniform [0,1–0.9990]
PRI 0<PRI<1 Uniform [0.0,1.0]
T0 (SOR) 0T00.35 Uniform [0.0,0.35]
T0 (SORI) 0T00.35 Uniform [0.0,0.35]
TR 0T010 Uniform [0.0,10.0]
β 0β0.1 Uniform [0,0.1]
q 0<q<1 Uniform [0,1.0]
χ1 0<χ1<10/(1000×364) Uniform [0,10/(1000*364)]
χ2 0<χ2<10/(1000×364) Uniform [0, 10/(1000*364)]
χ4 0<χ4<10/(1000×364) Uniform [0, 10/(1000*364)]
doi:10.1371/journal.pcbi.1004038.t004
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herd within our study population:HerdId links the animal record to a unique herd within our
study population:OccupancyTime is the number of days the animal remained on the herd after
its first on-movement;AgeOn is the age of the animal when it was moved onto the herd (0 for
births); LifeTime is the total number of days the animal lived (on any herd) and BreakAge is the
age of the animal on the disclosing test of the breakdown associated with that herd in the study
population. This information allows us to sample the timing of all of the demographic events oc-
curring to an individual over its lifetime: time of birth, time of movement off herd, time of death.
For each animal added to a herd at the start of a simulation we sample a row (i.e. a set of val-
ues ofOccupancyTime, AgeOn, LifeTime and BreakAge) from Table 9 and calculate the
birth, death and off times for that animal:
Birth_time = (t-BreakAge) + unif(0,0.001)
Death_time = Birth_time + LifeTime + unif(0,0.001)
Off_time = Birth_time +OccupancyTime + unif(0,0.001)
Where t is the current time and unif(0,0.001) is a uniformly distributed random number in
the range [0,0.001] added to ensure that each individual has a unique age, death and off
movement time.
Herd size is initialized to the number of animals present on the herd at the beginning of
breakdown associated with that herd. A constant population size is maintained by immediately
replacing animals that are removed from the herd (through either demographic processes or
testing) with a new animal. The birth, death and off times for each replacement animal are cal-
culated in a similar way by sampling a row from Table 9:
Birth_time = (t-AgeOn) + unif(0,0.001)
Table 6. Individual animal variables.
Data Field Data Type Description and Notes
Epi_status Enumeration (S,O,R,I,V1,V2,OV1,OV2,
RV,IV)
Epidemiological status
Birth_time Numeric (Days) Used to track age of individuals
Death_time Numeric (Days) Used to schedule removal from herd and book-keep denominator for slaughterhouse
surveillance
Off_time Numeric (Days) Used to schedule removal from herd and book-keep denominator for slaughterhouse
surveillance
Vaccinated_time Numeric (Days) Use to calculate probability of being SICCT positive
doi:10.1371/journal.pcbi.1004038.t006
Table 7. Markov events for SORI(V) stochastic transmission model.
Event Status Effect Probability per unit time
Infection S S!O bIþw
ðH=HmÞq
 
 RRðaÞ
V2 V2!OV2
Infection V1 V1!OV1 e bIþwðH=HmÞq
 
 RRðaÞ
Emergence (Occult) 0 0!R (1/T0)
OV1 OV1!RV
OV2 OV2!RV
Emergence (Reactive) R R!I (1/TR)
RV RV!IV
Loss of Protection V1 V1!V2 (1/TV)
doi:10.1371/journal.pcbi.1004038.t007
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Death_time = Birth_time + LifeTime + unif(0,0.001)
Off_time = Birth_time +OccupancyTime + unif(0,0.001)
In this way we model both births and cattle movements onto the herd, with the relative pro-
portion of replacement animals through births and on-movements determined by the CTS ex-
tract for that herd and the value of AgeOn. The CTS extract for all herds in the study
population is included as a supplementary data table (S1 Dataset).
SICCT testing model
SICCT testing, and the sequence of tests before, during and after a TB breakdown is modeled
as described previously in [7]. The sequence of tests before, during and after a breakdown is
simulated by a model where the timing of tests and number of animals to be tested changes dy-
namically according to the state-variables of the epidemic model and the outcome of individual
animal tests.
The model is initialised and then simulated forward, piecewise, between the dynamically
scheduled tests before, during and for 5 years following the end of the first breakdown, or until
a recurrent breakdown is triggered. The sequence of decisions following the outcome of herd
tests is summarized in S8 Fig.
Simulations begin with the herd undergoing routine surveillance through slaughterhouse
inspection and whole herd tests (classified as RHT or WHT) at 1, 2 or 4 yearly intervals corre-
sponding to the historical parish testing interval (PTI) for that herd. Detection of a reactor ani-
mal triggers a breakdown. The herd then enters a sequence of short interval tests (SIT).
Unconfirmed breakdowns end after a single clear test at the standard interpretation, while
confirmed breakdowns must clear two tests—one at severe interpretation and the second at
standard interpretation. Two follow-up tests, one six months after the end of a breakdown
(VE-6M) and one 12 months later (VE-12M) are then scheduled. The time between all tests as-
sociated with a breakdown (SIT, VE-6M, VE-12M) are sampled from empirical distributions
(S1 Dataset). The duration of time between routine tests is also sampled from an empirical
Table 8. Markov events for SOR(V) stochastic transmission model.
Event Status Effect Probability per unit time
Infection S S!O bIþw
ðH=HmÞq
 
 RRðaÞ
V2 V2!OV2
Infection V1 V1!OV1 e bIþwðH=HmÞq
 
 RRðaÞ
Emergence (Occult) 0 0!R (1/T0)
OV1 OV1!RV
OV2 OV2!RV
Loss of Protection V1 V1!V2 (1/TV)
doi:10.1371/journal.pcbi.1004038.t008
Table 9. Individual animal demographic data extract from cattle Tracing System (CTSTable).
Herd Id Occupancy Time Age On Life Time Break Age
Unique
herd ID
Days between animals recorded on-movement
and off-movement from herd
Age of animal when moved
onto herd (Days)
Days between animals birth
and death records
Age of animal on start date
of breakdown
doi:10.1371/journal.pcbi.1004038.t009
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distribution (with separate distributions for PTI 1, 2 and 4) to account for the additional varia-
tion in the time to detection that is a consequence of delays in testing and the transition of
herds between different parish testing intervals (S1 Dataset).
For tests associated directly with a breakdown (SIT, VE-6M, VE-12M) the whole herd
is tested. However, there is more variation in the type of test, and numbers of animals tested,
in PTI 2 and 4 herds. This variability in the number of animals tested is the consequence
of different eligibility criteria for animals based on their age and use. In our original models
we described this variability with empirical distributions. Within the individual based
model we can incorporate these eligibility criteria explicitly using the age of animals on
the date of a test and their scheduled exit date from the herd (which is pre-calculated as
described above). For whole herd tests (WHT) all animals older than 6 weeks are eligible
for testing, whereas for routine herd tests (RHT) animals must be older than 2 years to
be eligible.
Breakdowns are triggered by the detection of a reactor, either due to the presence of infected
animals in the herd or the generation of a false positive test result. Nominally, we simulate the
full sequence of tests until either of these events occurs with the proportion of false-positive
breakdowns determined by the relative values of the specificity and the infectious pressure. In
practice, and to increase the speed of simulations, this can be pre-calculated by explicitly calcu-
lating the probability of a false positive breakdown occurring between periods where there are
no infectious animals within the herd.
Age-stratified model of confirmation and slaughterhouse surveillance
As before, we simulate switching to the severe interpretation of the SICCT test used in OTF-W
breakdowns after the detection of visible lesions (VLs) within reactor animals. However, our
earlier models assumed that the probability of VLs being detected was constant per reactor—
clearly inconsistent with the pattern of age-dependence in reactor rates and presentation of le-
sions (Fig. 1). Our current model uses this empirical pattern to simulate the number of lesioned
animals in a test through a look-up table based on the animal’s age (Table 2). The lesion status
of each individual reactor is then simulated as a Bernoulli trial.
Slaughterhouse surveillance also depends on the detection of visible lesions, or culture con-
firmation carried out as part of routine carcass inspection. As such, Fig. 1 implies that the effi-
ciency of slaughterhouse surveillance should also depend on the age of the animal. We
therefore model the efficiency of slaughterhouse surveillance as the conditional probability of
detecting infected animals given that they have signs of visible lesionsPSL(a). We define the rela-
tive efficiency of slaughterhouse surveillance PRI compared to inspection of reactor animals
such that:
PSLðaÞ ¼ PRIPVLðaÞ
Vaccination and DIVA testing, assumptions and model parameters
Modelling the impact of vaccination requires additional model parameters that describe the in-
dividual level impact of vaccination and test characteristics of vaccinated animals (Table 10).
For all vaccination challenge scenarios, the herd is initialized with a whole herd vaccination
and a single infectious individual. The herd is then re-vaccinated on a strict annual cycle after
any scheduled whole herd test.
Our understanding of the mode of action of BCG through which animals are protected is
still incomplete. Our best estimates of vaccine efficacy come from natural transmission studies
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[4], [5]. In these studies vaccinated animals have been found to be free of disease suggesting
that sterilizing immunity is possible. However, given the necessarily limited timescale of these
trials it is also possible that BCG is simply acting to slow the rate of progression to detectable
disease. Challenge experiments have demonstrated such an effect of BCG with a significant re-
duction in pathology in inoculated vaccinates, but no sterilizing immunity [2]. However, given
that the effective dose under natural transmission may be lower than under artificial challenge
these data do not rule out the possibility that BCG also reduces the susceptibility of individual
cattle. Given that there are no data to inform the magnitude of the impact that BCG may have
on rates of progression we choose to model the individual level protective effect of vaccination
through a single parameter (ε) that describes the per-capita reduction in the risk of vaccinated
animals acquiring infection. This choice of parameterisation also has the advantage of corre-
sponding closely to the definition of vaccine efficacy as estimated from natural
transmission studies.
Given the relative paucity of evidence described for reduction in the severity of disease for
vaccinates, we assumed that rates of progression for infected vaccinates were unchanged. Loss
of protection of vaccinates is modeled by introducing two vaccinate statuses (V1,OV1,V2,OV2)
that are assumed to have the same basic test characteristics but differ only in their relative risk
of infection (S7 Fig., Tables 7 and 8). Protection is assumed to be lost at a constant rate with the
average duration of protection fixed at 1 year [2], [33]. Data on the effect of re-vaccination are
lacking. In the absence of this important information we treat re-vaccinated animals in exactly
the same way as newly vaccinated animals. As a consequence, our model may overestimate
both the individual level protection of re-vaccinated animals and their sensitivity to tuberculin
testing (as described below).
DIVA testing is modeled by an assumed DIVA sensitivity pDand specificity 1-pDFP defined
relative to the true infection and vaccination status of animals (Table 10). An important data
gap should be highlighted, in that as with all bTB tests, the empirical estimates of current gen-
eration DIVA tests are estimated relative to the presence or absence of visible lesions. The po-
tential misclassification of infected individuals by this imperfect gold standard measurement
complicates the translation of empirical estimates of test characteristics to model parameters.
In the absence of a true gold-standard test, the relationship between true test characteristics
and relative measures cannot be modeled a priori and care must be taken in comparing be-
tween the absolute values of these parameters used within the model and relative values that
would be estimated relative to visible lesions or culture.
Tuberculin testing of vaccinates
Although the sensitizing effect of BCG vaccination on tuberculin testing is well known, quanti-
tative data on the impact of BCG on test status are limited to a single challenge study carried
Table 10. Vaccination model parameters.
Parameter Description
pD DIVA sensitivity Probability of positive DIVA test in infected vaccinates (V1,V2,OV1,0V2,RV,
IV).
1-pDFP DIVA speciﬁcity Probability of negative DIVA test for uninfected vaccinates (V1,V2)
(1—probability of a false positive pDFP)
ε Vaccine Efﬁcacy Reduction in risk of infection for vaccinates (status V1)
TV Protective Period. Mean length of time that animals are protected by BCG vaccination
(status V1)
doi:10.1371/journal.pcbi.1004038.t010
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out by AHVLA [6]. BCG vaccinates were SICCT tested at 90, 180, 270, 450 and 720 days post
vaccination. Skin test measurements were then interpreted at the standard and severe interpre-
tation and the probability of animals being classified as a reactor calculated (Table 11). We use
these empirical data within our model to define the specificity of SICCT vaccinated animals.
As a consequence of the sampling frequency of this experiment our model will underestimate
the reactivity within the first 90 days post-inoculation (which we define as 0). There is a further
data gap with respect to the sensitization after 2 years and on re-vaccination. We assume that
the specificity of vaccinates takes a constant value post 720 days, and that re-vaccination leads
to the same time-dependent pattern of sensitization relative to the time of revaccination. As a
consequence of these assumptions our model will likely underestimate the number of false pos-
itive reactor animals in the first 90 days post-vaccination.
We model the sensitization of BCG vaccinates to tuberculin using a time-dependent proba-
bility of an animal being classified as a reactor estimated from challenge studies carried out by
AHVLA [6]. The probability of being classified as a reactor is assumed to be constant with
coarse-grained 90-day intervals and take the same constant value for all animals older than
720 days.
Supporting Information
S1 Fig. Parameter distributions estimated by ABC for SORI model. Parameter distributions
estimated for SORI model by ABC-SMC. Distributions of parameters most consistent with per-
sistence, surveillance and reactor distributions estimated from VetNet data (Summarised in
Fig. 1) conditional on our prior assumptions (Table 4). Each approximate posterior distribu-
tion is plotted on the range of the (uniform) prior distributions for each parameter. Sensitivity
and specificity parameters are further constrained such that the severe interpretation always
has a higher sensitivity and lower specificity (Panels A,B). On panel B a dashed vertical line in-
dicates the lower bound of the prior distribution for specificity at the standard interpretation.
(TIF)
S2 Fig. Parameter distributions estimated by ABC for SOR model. Parameter distributions
estimated for SOR model by ABC-SMC. Distributions of parameters most consistent with
Table 11. Time-dependent sensitisation of vaccinates to SICCT [6].
Time from Vaccination (Days) SICCT Interpretation Probability classiﬁed as reactor
0–90 Standard 0.0
Severe 0.0
90–180 Standard 0.60
Severe 0.84
180–270 Standard 0.80
Severe 0.95
270–360 Standard 0.09
Severe 0.30
360–450 Standard 0.05
Severe 0.10
450–720 Standard 0.11
Severe 0.30
720+ Standard 0.10
Severe 0.30
doi:10.1371/journal.pcbi.1004038.t011
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persistence, surveillance and reactor distributions estimated from VetNet data (Summarised in
Fig. 1) conditional on our prior assumptions (Table 4). Each approximate posterior distribu-
tion is plotted on the range of the (uniform) prior distributions for each parameter. Sensitivity
and specificity parameters are further constrained such that the severe interpretation always
has a higher sensitivity and lower specificity (Panels A,B). On panel B a dashed vertical line in-
dicates the lower bound of the prior distribution for specificity at the standard interpretation.
(TIF)
S3 Fig. Predictive distributions for SOR model compared to persistence metrics (2003–
2011).Within-herd measures of persistence and surveillance used as target metrics for ABC
and to assess model fit. We present four key measures, from left to right: the proportion of pro-
longed (restrictions of greater duration than 240 days) and recurrent breakdowns, the propor-
tion of herds with evidence of visible lesions and the total number of reactors per breakdown.
Breakdowns are classified as either OTF-S (officially TB free suspended), where no reactors are
found to have visible lesions (lime green circles), or OTF-W (officially TB free withdrawn)
where at least one reactor was found to have evidence of visible lesions or be culture positive
(magenta squares). The proportion of such OTF-W breakdowns is shown along with the pro-
portion of these that were initiated by a slaughterhouse case (black circles). The relationship of
each measure with herd size is plotted, with breakdowns further stratified by the historical par-
ish testing interval (A, PTI1; B, PTI 2; C PTI 4) and breakdown status. Mean target observa-
tions are plotted with uncertainty estimated as ±1.96 standard errors around the mean.
Predictive distributions from our within-herd (SOR) model for each of these measures are plot-
ted as shaded density strips where the intensity of color is proportional to the probability densi-
ty at that point [34].
(TIF)
S4 Fig. SOR model predictive distributions for age of reactors. SOR model predictive distri-
butions for the age of reactors (A). Age of “confirmed” reactors with evidence of visible lesions
(B). Slaughterhouse cases (C) and the proportion of animals with visible lesions stratified by
age (D). Solid points and lines indicate empirical target distributions, model predictive distri-
butions are once again overplotted as shaded density strips where the intensity of color is pro-
portional to the probability density at that point [34].
(TIF)
S5 Fig. Break-even points for vaccine efficacy under alternative testing scenarios using
γ-DIVA test (SORmodel).We estimate the break-even point for a protective benefit of BCG
vaccination at the herd level under three alternative testing scenarios. We model DIVA testing
using parameter estimates that optimize DIVA specificity of 99.4% under the constraint of
maintaining a DIVA sensitivity comparable to tuberculin testing of 64.4%. We consider four
key measures of the epidemiological, and economic, costs associated with bTB testing: A the
number of animals condemned as reactors; B the number of tests (tuberculin and DIVA) need-
ed to clear restrictions; C The number of infected animals left in herds after restrictions are
lifted (burden of infection missed by testing)D The number of herds that experience a break-
down before the herd clears the singleton challenge. For all panels, solid black lines indicate the
median break-even point for the baseline scenario with no vaccination. Dashed lines indicate
the 95% quantiles of the baseline scenario. The distribution for each measure is calculated from
100 simulations with parameters drawn from the (approximate) posterior distributions of our
estimated model, with each parameter set simulated once for each herd within our representa-
tive study population (of 6,601 herds).
(TIF)
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S6 Fig. Probability of a protective herd level benefit of vaccination for alternative DIVA
testing strategies (SOR model).We explore how the probability of seeing a protective benefit
of vaccination depends on the assumed sensitivity and specificity of DIVA testing. The proba-
bility of benefit is calculated for a singleton challenge of infection and relative to the current
statutory regime of tuberculin testing and slaughterhouse surveillance. Benefit is estimated
from 100 simulations of our study population (6,601 herds) for three key measures (across col-
umns): the total number of tests required to clear restrictions (A,D,G), the probability of re-
strictions being applied before the herd clears infection (B,E,H) and the probability of
infection remaining in a herd when restrictions are lifted (C,F,I). We define the break-even
point as 50% of herds demonstrating a protective benefit illustrated by the white band in the
color map with red values worse this threshold and grey points better. We compare the three
strategies described in the main text (across rows): (A,B,C) Under the DIVA negation scenario,
the break-even point is limited by the considerable overhead in testing, with an increased prob-
ability of restrictions being applied before the herd clears infection (B) and an increase in test-
ing (A) even for a 100% sensitive and specific DIVA test. (D,E,F) Under DIVA replacement, a
protective benefit of vaccination can be achieved for DIVA specificities> 99.90% (D). The
break-even point also depends on DIVA sensitivity, with a sensitivity of at least 40% being nec-
essary to avoid increased risk of leaving infection in the herd after restrictions are lifted (F).
(G,H,I) Under the VLend scenario, linking the maintenance of restrictions to detection of le-
sioned reactor animals mitigates the addition costs of testing under other scenarios (G). How-
ever, a specificity of greater than 99.85% is still required to see no increase in the number of
breakdowns with vaccination (H), with the break-even point depending again on a DIVA sen-
sitivity of greater than 40% (I).
(TIF)
S7 Fig. Compartmental structure of epidemiological models.
(TIF)
S8 Fig. Sequence of testing before, during and after disclosure of infection in a herd.
(TIF)
S9 Fig. Alternative version of Fig. 4: Break-even points for vaccine efficacy under alterna-
tive testing scenarios using γ-DIVA test.We estimate the break-even point for a protective
benefit of BCG vaccination at the herd level under three alternative testing scenarios. We
model DIVA testing using parameter estimates that optimize DIVA specificity of 99.4% under
the constraint of maintaining a DIVA sensitivity comparable to tuberculin testing of 64.4%.
We consider four key measures of the epidemiological, and economic, costs associated with
bTB testing: A the number of animals condemned as reactors; B the number of tests (tubercu-
lin and DIVA) needed to clear restrictions; C The number of infected animals left in herds
after restrictions are lifted (burden of infection missed by testing)D The number of herds that
experience a breakdown before the herd clears the singleton challenge. For all panels, solid
black lines indicate the median break-even point for the baseline scenario with no vaccination.
Dashed lines indicate the 95% quantiles of the baseline scenario. The distribution for each mea-
sure is calculated from 100 simulations with parameters drawn from the (approximate) poste-
rior distributions of our estimated model, with each parameter set simulated once for each
herd within our representative study population (of 6,601 herds).
(TIF)
S10 Fig. Alternative version of S5 Fig.: Break-even points for vaccine efficacy under alterna-
tive testing scenarios using γ-DIVA test (SOR model).We estimate the break-even point for
a protective benefit of BCG vaccination at the herd level under three alternative testing
Cattle Vaccination for Bovine Tuberculosis
PLOS Computational Biology | DOI:10.1371/journal.pcbi.1004038 February 19, 2015 24 / 26
scenarios. We model DIVA testing using parameter estimates that optimize DIVA specificity
of 99.4% under the constraint of maintaining a DIVA sensitivity comparable to tuberculin test-
ing of 64.4%. We consider four key measures of the epidemiological, and economic, costs asso-
ciated with bTB testing: A the number of animals condemned as reactors; B the number of
tests (tuberculin and DIVA) needed to clear restrictions; C The number of infected animals left
in herds after restrictions are lifted (burden of infection missed by testing)D The number of
herds that experience a breakdown before the herd clears the singleton challenge. For all panels,
solid black lines indicate the median break-even point for the baseline scenario with no vacci-
nation. Dashed lines indicate the 95% quantiles of the baseline scenario. The distribution for
each measure is calculated from 100 simulations with parameters drawn from the (approxi-
mate) posterior distributions of our estimated model, with each parameter set simulated once
for each herd within our representative study population (of 6,601 herds).
(TIF)
S1 Dataset. Data tables defining herd demography and target epidemiological metrics.
(ZIP)
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